[HTML][HTML] Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

…, T Kinoshita, M Fujii, A Nashimoto… - … England Journal of …, 2007 - Mass Medical Soc
Background Advanced gastric cancer can respond to S-1, an oral fluoropyrimidine. We tested
S-1 as adjuvant chemotherapy in patients with curatively resected gastric cancer. Methods …

[PDF][PDF] Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer

…, H Furukawa, T Yamaguchi, A Nashimoto… - J clin …, 2011 - researchgate.net
Purpose The first planned interim analysis (median follow-up, 3 years) of the Adjuvant
Chemotherapy Trial of S-1 for Gastric Cancer confirmed that the oral fluoropyrimidine derivative S-…

[HTML][HTML] D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer

…, S Yamamoto, Y Kurokawa, A Nashimoto… - … England Journal of …, 2008 - Mass Medical Soc
Background Gastrectomy with D2 lymphadenectomy is the standard treatment for curable
gastric cancer in eastern Asia. Whether the addition of para-aortic nodal dissection (PAND) to …

[PDF][PDF] Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy …

…, M Sasako, S Yamamoto, A Nashimoto… - Journal of clinical …, 2004 - academia.edu
Purpose Radical gastrectomy with regional lymphadenectomy is the only curative treatment
option for gastric cancer. The extent of lymphadenectomy, however, is controversial. The two …

Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial

…, M Sairenji, K Arai, T Kinoshita, A Nashimoto… - The lancet …, 2006 - thelancet.com
Background Because of the inaccessibility of mediastinal nodal metastases, the left
thoracoabdominal approach (LTA) has often been used to treat gastric cancer of the cardia or …

[HTML][HTML] Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry

A Nashimoto, K Akazawa, Y Isobe, I Miyashiro, H Katai… - Gastric cancer, 2013 - Springer
Background The Japanese Gastric Cancer Association (JGCA) started a new nationwide
gastric cancer registration in 2008. Methods From 208 participating hospitals, 53 items …

[HTML][HTML] Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide …

…, T Fukagawa, S Nunobe, Y Kakeji, A Nashimoto… - Gastric cancer, 2018 - Springer
Background The aim of this retrospective study was to investigate the tumor characteristics,
surgical details, and survival distribution of surgically resected cases of gastric cancer from …

Expression of glucose transporter‐1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival

…, K Watanabe, T Fukuda, A Nashimoto… - … Journal of the …, 2001 - Wiley Online Library
BACKGROUND Malignant cells show increased glucose uptake in vitro and in vivo, which
is believed to be facilitated by glucose transporters (Gluts). Expression of Glut1, one of the …

[HTML][HTML] Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry

Y Isobe, A Nashimoto, K Akazawa, I Oda, K Hayashi… - Gastric Cancer, 2011 - Springer
The Japanese Gastric Cancer Association (JGCA) started a new nationwide gastric cancer
registry in 2008. Approximately 50 data items, including surgical procedures, pathological …

Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis …

…, Y Fujiwara, R Fukushima, A Nashimoto… - Journal of Clinical …, 2018 - ascopubs.org
Purpose Intraperitoneal paclitaxel plus systemic chemotherapy demonstrated promising
clinical effects in patients with gastric cancer with peritoneal metastasis. We aimed to verify its …